Literature DB >> 2449867

Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF.

R L Hopfer1, R Mehta, G Lopez-Berestein.   

Abstract

Amphotericin B (AmpB) disrupts membrane integrity by binding to sterols in fungal and mammalian cell membranes. The gramicidins, which form pores in all membranes but exhibit poor antifungal activity, are too toxic to mammalian cells to be used systemically. This study demonstrated synergistic antifungal activity of free and liposomal forms of AmpB when combined with the free and liposomal forms of gramicidin S and gramicidin NF against five Candida strains. In vitro erythrocyte lysis was prevented by using the liposomal forms of all drugs tested alone or in combination. Presumably, AmpB increases accessibility of the fungal cell membrane to the gramicidins, while liposome encapsulation decreases the rate of transfer of the drugs to the mammalian cell membrane. Liposome encapsulation of inactive or toxic drugs, used in combination with liposomal AmpB, may give new life to drugs previously believed to be inactive or too toxic for therapeutic consideration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2449867      PMCID: PMC175838          DOI: 10.1128/AAC.31.12.1978

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites.

Authors:  G B ELION; S SINGER; G H HITCHINGS
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

2.  The release of potassium ions from Candida albicans in the presence of polyene antibiotics.

Authors:  E F Gale
Journal:  J Gen Microbiol       Date:  1974-02

3.  Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice.

Authors:  C Tremblay; M Barza; C Fiore; F Szoka
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  Adherence of candida species to intravenous catheters.

Authors:  D Rotrosen; T R Gibson; J E Edwards
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

5.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R Mehta; R L Hopfer; K Mills; L Kasi; K Mehta; V Fainstein; M Luna; E M Hersh; R Juliano
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

6.  In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B.

Authors:  R L Hopfer; K Mills; R Mehta; G Lopez-Berestein; V Fainstein; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Authors:  G Lopez-Berestein; V Fainstein; R Hopfer; K Mehta; M P Sullivan; M Keating; M G Rosenblum; R Mehta; M Luna; E M Hersh
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

8.  Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells.

Authors:  R Mehta; G Lopez-Berestein; R Hopfer; K Mills; R L Juliano
Journal:  Biochim Biophys Acta       Date:  1984-03-14

9.  Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics.

Authors:  J Brajtburg; D Kobayashi; G Medoff; G S Kobayashi
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

10.  Hydrophobic interaction in Candida albicans and Candida tropicalis adherence to various denture base resin materials.

Authors:  S Minagi; Y Miyake; K Inagaki; H Tsuru; H Suginaka
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

View more
  6 in total

Review 1.  In vitro and in vivo evaluation of antifungal agents.

Authors:  A Espinel-Ingroff; S Shadomy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

Review 2.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

3.  Effects of free and liposomal amphotericin B and gramicidin S alone and in combination on potassium leakage from human erythrocytes and Candida albicans.

Authors:  J A Midez; R L Hopfer; G Lopez-Berestein; R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

4.  Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.

Authors:  V Joly; J Bolard; L Saint-Julien; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 5.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

6.  Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK 506) in rats.

Authors:  M J Lee; R M Straubinger; W J Jusko
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.